For example, Ramucirumab, a monoclonal selective VEGFR2 antibody has been observed to suppressive VEGFR2, which decreased M2 infiltration and inhibited the production of chemokine, which in turn delay GC tumor progress.54 This evidence concerns the gene KDR and neoplasm.